Mr. Connor and his team at Vanderbilt designed, manufactured, and evaluated a stone retrieval device with an independently ...

While MRI-targeted biopsy (TB) has improved prostate cancer detection, systematic biopsy (SB) remains a critical complementary approach, often identifying csPCa missed by TB. However, the optimal ...

(UroToday.com) Today at the Engineering and Urology Society (EUS) Poster Session, Dr. Dan Stoianovici presented early clinical experience with ProBot, a newly developed robotic system designed to ...

Dr. Madison Lyon presented a study on a novel wireless catheter-free ambulatory urodynamic device called UroMonitor (UM) in male patients (Figure 1). Multichannel urodynamics (UDS) is the conventional ...

Multiple case reports have discussed late repairs from 7 to 42 days with low rates of erectile dysfunction or penile curvature, albeit with short follow-up. Due ot the nature of the disease, there is ...

AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Laura Mertens, with a debate between Drs. Joshua Meeks and ...

In a study from Dr. Zlotta’s group published in 2025 in the Journal of Urology, 1 they suggest that better tools are needed to minimize interobserver variability in pathological grading. This is ...

(UroToday.com) Dr. Alejandro Bautista-Pérez-Gavilán discussed his new work on going previously developed gold and silver nanoparticle coatings that have anti-microbial activity. At last year’s AUA, Dr ...

AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Peter Black, with a debate between Drs. Wes Kassouf and ...

The study investigators identified 24 prospective trials with 2,850 patients. The median patient age ranged between 59 and 77 years. Overall, testosterone recovery, defined at 240 ng/dL, was observed ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...

Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration ...